A pre-endoscopy debate that isn’t about technique so much as timing and patient experience
Personally, I think the real story here isn’t whether GLP-1 or GIP agonists should be held or continued before an endoscopic procedure. It’s about how we balance pharmacology, patient comfort, and procedural safety in a field where tiny decisions can ripple into bigger outcomes. The latest randomized trial adds a provocative twist: continuing these incretin-mimetic drugs in the preprocedural window raises the odds of a clinically significant residual gastric volume (RGV), but it doesn’t seem to lift the risk of other adverse events. That nuance matters because it forces clinicians to weigh two competing priorities—ensuring the stomach is as clear as possible for the procedure, while not unduly hampering symptom control or glucose management for patients who rely on these medications for chronic conditions.
What makes this particularly interesting is the practical implication for everyday practice. If continuing GLP-1 or GIP agonists does increase residual gastric volume, why doesn’t that automatically translate into more complications? My interpretation is that the gastric contents may be more present, but not in ways that measurably harm short-term safety in the perioperative period. This hints at a larger trend: pharmacologic effects we observe in controlled studies may not always map neatly onto real-world risk, especially when the outcome measured is a specific radiographic or volume-based parameter rather than a broad safety endpoint. From my perspective, that disconnect invites a more nuanced, patient-centered approach than a one-size-fits-all rule.
Rethinking the timing question: hold or continue?
- The core finding: continuing GLP-1/GIP agonists prior to endoscopy increases clinically significant RGV but does not elevate overall adverse events. What this means is that gastric emptying can be slowed enough to matter for the endoscopist's view and technique, yet not so much that it precipitates complications like aspiration or airway issues in the short term.
- Personal interpretation: this creates a gray zone. If a patient’s endoscopy is high-stakes for diagnostic yield or therapeutic maneuvering, a clinician might prefer to pause the drug to reduce residual volume. Conversely, if stopping the medication would destabilize glycemic control or exacerbate symptoms for a patient with diabetes or obesity, continuing could be defensible, provided the team is prepared to manage the slightly cloudier gastric field.
- Why it matters: decisions about preprocedural medication timing intersect with patient safety, workflow efficiency, and resource use. Anesthesia teams and endoscopy units crave predictability; this study injects a dose of nuance that can help tailor plans rather than impose blanket directives.
- What people often misunderstand: a higher residually present volume isn’t automatically a predictor of dire events. The body can tolerate certain levels of gastric content if aspiration risk, airway protection, and suctioning readiness are well managed. The takeaway isn’t “always hold,” but “assess risk in context.”
Could clear liquids offer a simple path forward?
The study suggests that providing clear liquids the day before the procedure may mitigate the risk of clinically significant RGV regardless of GLP-1/GIP use. That’s an accessible, low-cost intervention with potential to harmonize practice. From my vantage point, this points to a practical standard that respects both pharmacology and patient comfort: flexible preprocedural nutrition policies paired with clear protocol for those on incretin-based therapies.
- Personal interpretation: embracing a light fasting trajectory that includes clear fluids up to a certain cut-off could preserve gastric clarity while maintaining metabolic stability. It’s a compromise that acknowledges patient needs without sacrificing procedural integrity.
- Why it matters: policy implications extend beyond one trial. If reproduced, this approach could become a standardized recommendation, reducing variability between centers and improving patient experience during preprocedure preparation.
- What people don’t realize: even small changes in preprocedural instructions can influence patient adherence. Clear-liquid guidance is easier to implement and communicate, potentially reducing last-minute cancellations or anxious questions about “what I can drink.”
Broader implications for practice and research
One thing that immediately stands out is the tension between pharmacologic effect and procedural outcomes. GLP-1/GIP agonists have become a mainstay for metabolic conditions, yet their impact on perioperative pathways remains underappreciated in routine guidelines. This study nudges us to think beyond the macro questions of “hold or continue” and toward a more integrated perioperative plan that accounts for medication effects, diet, and procedural goals.
- What this really suggests is a need for individualized preprocedure plans. Rather than sweeping prohibitions, clinicians could map a patient’s metabolic control, endoscopic urgency, and tolerance for residual gastric contents to craft a bespoke approach.
- A detail that I find especially interesting is how this intersects with patient education. If clear liquids can help, patients should be coached on the rationale and the practical steps to maintain safety without unnecessary hardship or fear of cancelation.
- In terms of future developments, we may see more granular risk stratification tools that quantify residual gastric volume risk versus procedural benefit, leading to dynamic guidelines that adapt to patient-specific factors and procedure type.
Deeper reflection on the patient voice and system efficiency
From my perspective, the heart of this issue isn’t merely pharmacology or radiographic measurements. It’s about respecting patient dignity in the preprocedure process and acknowledging the real-world tradeoffs clinicians face. For some patients, GLP-1/GIP therapies are lifelines that improve quality of life; halting them right before a procedure could trigger symptoms, unstable glucose, or emotional stress. For others, a slightly cloudier gastric field may be an acceptable risk for the sake of a higher likelihood of a smooth procedure. The art is in balancing these strands with clear communication, shared decision-making, and pragmatic protocols.
A provocative takeaway
If you take a step back and think about it, the core question becomes: how can we design perioperative pathways that are evidence-informed, patient-centered, and operationally robust? The current findings push us toward a more nuanced, flexible framework rather than rigid rules. And, frankly, that’s refreshing. It acknowledges complexity rather than pretending there’s a perfect, one-size-fits-all answer.
Conclusion: a shift toward calibrated flexibility
Ultimately, this line of research invites clinicians to calibrate their approach to preprocedural medication and nutrition with greater precision. The goal isn’t to police who can take their GLP-1/GIP agonist to the endoscopy suite, but to ensure that each patient receives a tailored plan that optimizes both safety and comfort. In my view, the most valuable outcome will be the development of clear, adaptable guidelines that incorporate these insights, paired with practical education for patients and care teams. If we can achieve that, we’ll move closer to endoscopy as a smoother, more patient-friendly experience without compromising diagnostic or therapeutic potential.
